Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer
jRCT2080223752Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in colorectal adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd. Started Dec 2017; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2080223752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223752.